Molecular Interactions of Prodiginines with the BH3 Domain of Anti-Apoptotic Bcl-2 Family Members

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Hosseini, Ali ^a   Espona Fiedler, Margarita ^b   Soto Cerrato, Vanessa ^b   Quesada, Roberto ^c   Pérez Tomás, Ricardo ^b   Guallar, Victor ^a,d  

^a INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITY OF BURGOS   (Spain)

^d INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ANTINEOPLASTIC AGENT; APOPTOSIS INHIBITOR; BH3 PROTEIN; OBATOCLAX; PRODIGININE; PRODIGIOSIN; PROTEIN BAK; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BINDING AFFINITY; COMPLEX FORMATION; COMPUTER MODEL; COMPUTER PROGRAM; COMPUTER SIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME ACTIVATION; EXPERIMENTAL STUDY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; INTRACELLULAR SIGNALING; MATHEMATICAL COMPUTING; MELANOMA CELL; MOLECULAR INTERACTION; PROTEIN DOMAIN; PROTEIN FUNCTION;

APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LIGANDS; MITOCHONDRIA; MOLECULAR DOCKING SIMULATION; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PRODIGIOSIN; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84874529604     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057562     Document Type: Article

References (44)

1. Perez-Tomas R, Vinas M, (2010) New Insights on the Antitumoral Properties of Prodiginines. Current Medicinal Chemistry 17: 2222-2231.
2. Soto-Cerrato V, Llagostera E, Montaner B, Scheffer GL, Perez-Tomas R, (2004) Mitochondria-mediated apoptosis operating irrespective of multidrug resistance in breast cancer cells by the anticancer agent prodigiosin. Biochem Pharmacol 68: 1345-1352.
3. Soto-Cerrato V, Vinals F, Lambert JR, Kelly JA, Perez-Tomas R, (2007) Prodigiosin induces the proapoptotic gene NAG-1 via glycogen synthase kinase-3beta activity in human breast cancer cells. Mol Cancer Ther 6: 362-369.
4. Ho TF, Peng YT, Chuang SM, Lin SC, Feng BL, et al. (2009) Prodigiosin down-regulates survivin to facilitate paclitaxel sensitization in human breast carcinoma cell lines. Toxicol Appl Pharmacol 235: 253-260.
5. Hsieh HY, Shieh JJ, Chen CJ, Pan MY, Yang SY, et al. (2012) Prodigiosin down-regulates SKP2 to induce p27(KIP1) stabilization and antiproliferation in human lung adenocarcinoma cells. Br J Pharmacol 166: 2095-2108.
6. Lu CH, Lin SC, Yang SY, Pan MY, Lin YW, et al. (2012) Prodigiosin-induced cytotoxicity involves RAD51 down-regulation through the JNK and p38 MAPK pathways in human breast carcinoma cell lines. Toxicol Lett 212: 83-89.
7. Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, et al. (2007) Apoptosis Initiated When BH3 Ligands Engage Multiple Bcl-2 Homologs, Not Bax or Bak. Science 315: 856-859.
8. Kazi A, Sun J, Doi K, Sung S-S, Takahashi Y, et al. (2011) The BH3 α-Helical Mimic BH3-M6 Disrupts Bcl-XL, Bcl-2, and MCL-1 Protein-Protein Interactions with Bax, Bak, Bad, or Bim and Induces Apoptosis in a Bax- and Bim-dependent Manner. Journal of Biological Chemistry 286: 9382-9392.
9. Chonghaile TN, Letai A, (2008) Mimicking the BH3 domain to kill cancer cells. Oncogene 27: S149-S157.
10. Zhai D, Jin C, Satterthwait AC, Reed JC, (2006) Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ 13: 1419-1421.
11. Parikh SA, Kantarjian H, Schimmer A, Walsh W, Asatiani E, et al. (2010) Phase II Study of Obatoclax Mesylate (GX15-070), a Small-Molecule BCL-2 Family Antagonist, for Patients With Myelofibrosis. Clinical Lymphoma Myeloma and Leukemia 10: 285-289.
12. Konopleva M, Watt J, Contractor R, Tsao T, Harris D, et al. (2008) Mechanisms of Antileukemic Activity of the Novel Bcl-2 Homology Domain-3 Mimetic GX15-070 (Obatoclax). Cancer Research 68: 3413-3420.
13. Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, et al. (2007) Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proceedings of the National Academy of Sciences 104: 19512-19517.
14. Espona-Fiedler M, Soto-Cerrato V, Hosseini A, Lizcano JM, Guallar V, et al. (2012) Identification of dual mTORC1 and mTORC2 inhibitors in melanoma cells: Prodigiosin vs. obatoclax. Biochemical Pharmacology 83: 489-496.
15. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, et al. (2005) Differential Targeting of Prosurvival Bcl-2 Proteins by Their BH3-Only Ligands Allows Complementary Apoptotic Function. Molecular cell 17: 393-403.
16. Certo M, Moore VDG, Nishino M, Wei G, Korsmeyer S, et al. (2006) Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer cell 9: 351-365.
17. Ku B, Liang C, Jung JU, Oh B-H, (2011) Evidence that inhibition of BAX activation by BCL-2 involves its tight and preferential interaction with the BH3 domain of BAX. Cell Res 21: 627-641.
18. Díaz de Greñu B, Hernández PI, Espona M, Quiñonero D, Light ME, et al. (2011) Synthetic Prodiginine Obatoclax (GX15-070) and Related Analogues: Anion Binding, Transmembrane Transport, and Cytotoxicity Properties. Chemistry - A European Journal 17: 14074-14083.
19. Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR, (2006) Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell 21: 749-760.
20. Mosmann T, (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63.
21. Borrelli K, Vitalis A, Alcantara R, Guallar V, (2005) PELE: Protein Energy Landscape Exploration. A Novel Monte Carlo Based Technique. Journal of Chemical Theory and Computation 1: 1304-1311.
22. (2010) Glide. version 5.6 ed. New York, NY: LLC: Schrödinger.
23. Borrelli KW, Cossins B, Guallar V, (2010) Exploring hierarchical refinement techniques for induced fit docking with protein and ligand flexibility. Journal of Computational Chemistry 31: 1224-1235.
24. Cossins BP, Hosseini A, Guallar V, (2012) Exploration of Protein Conformational Change with PELE and Meta-Dynamics. Journal of Chemical Theory and Computation 8: 959-965.
25. Czabotar PE, Lee EF, van Delft MF, Day CL, Smith BJ, et al. (2007) Structural insights into the degradation of Mcl-1 induced by BH3 domains. Proceedings of the National Academy of Sciences 104: 6217-6222.
26. Bernardo PH, Sivaraman T, Wan K-F, Xu J, Krishnamoorthy J, et al. (2010) Structural Insights into the Design of Small Molecule Inhibitors That Selectively Antagonize Mcl-1. Journal of Medicinal Chemistry 53: 2314-2318.
27. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, et al. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435: 677-681.
28. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, et al. (2006) The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer cell 10: 389-399.
29. Lee EF, Czabotar PE, Smith BJ, Deshayes K, Zobel K, et al. (2007) Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family. Cell Death Differ 14: 1711-1713.
30. (2011) Protein Preparation Wizard. Epik version 2.2, Impact version 5.7, Prime version 3.0 ed. New York, NY: Schrödinger, LLC.
31. (2011) SiteMap. version 2.5 ed. New York, NY: Schrödinger, LLC.
32. Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, et al. (2006) Extra Precision Glide: Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein-Ligand Complexes. Journal of Medicinal Chemistry 49: 6177-6196.
33. Willis SN, Chen L, Dewson G, Wei A, Naik E, et al. (2005) Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes & Development 19: 1294-1305.
34. Trudel S, Li ZH, Rauw J, Tiedemann RE, Wen XY, et al. (2007) Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood 109: 5430-5438.
35. Boersma MD, Haase HS, Peterson-Kaufman KJ, Lee EF, Clarke OB, et al. (2011) Evaluation of Diverse α/β-Backbone Patterns for Functional α-Helix Mimicry: Analogues of the Bim BH3 Domain. Journal of the American Chemical Society 134: 315-323.
36. Smits C, Czabotar PE, Hinds MG, Day CL, (2008) Structural Plasticity Underpins Promiscuous Binding of the Prosurvival Protein A1. Structure (London, England: 1993) 16: 818-829.
37. Day CL, Chen L, Richardson SJ, Harrison PJ, Huang DCS, et al. (2005) Solution Structure of Prosurvival Mcl-1 and Characterization of Its Binding by Proapoptotic BH3-only Ligands. Journal of Biological Chemistry 280: 4738-4744.
38. Acoca S, Cui Q, Shore GC, Purisima EO, (2011) Molecular dynamics study of small molecule inhibitors of the Bcl-2 family. Proteins: Structure, Function, and Bioinformatics 79: 2624-2636.
39. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, et al. (2009) Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2. PLoS Biol 7: e1000038.
40. Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, et al. (2011) Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors. Journal of Clinical Oncology 29: 909-916.
41. Dong L, Jiang CC, Thorne RF, Croft A, Yang F, et al. (2011) Ets-1 mediates upregulation of Mcl-1 downstream of XBP-1 in human melanoma cells upon ER stress. Oncogene 30: 3716-3726.
42. Li J, Viallet J, Haura E, (2008) A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells. Cancer Chemotherapy and Pharmacology 61: 525-534.
43. Martin AP, Park MA, Mitchell C, Walker T, Rahmani M, et al. (2009) BCL-2 Family Inhibitors Enhance Histone Deacetylase Inhibitor and Sorafenib Lethality via Autophagy and Overcome Blockade of the Extrinsic Pathway to Facilitate Killing. Molecular Pharmacology 76: 327-341.
44. Rahmani M, Aust MM, Attkisson E, Williams DC, Ferreira-Gonzalez A, et al. (2012) Inhibition of Bcl-2 anti-apoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process. Bloo 119: 6089-6098.